Seeking Alpha

Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff...

Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff Meacham says, reiterating an Overweight rating on shares of Medivation (MDVN -9.3%) which are currently in a tailspin following JNJ's acquisition of Aragon (I, II). Meacham acknowledges that Aragon's cause (both from a legal and development perspective) will be helped by JNJ's substantial resources, but notes that early stage prostate cancer agents face "significant clinical, regulatory, and commercial hurdles."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)